University of Fribourg - Chair of Pharmacology

Cancer immunotherapy has reached a breakthrough in 2013 with the advent of drugs based on immune checkpoint blockade. However, even the most effective treatment options in immunotherapy result in an objective clinical response in only a minority of patients. One reason may be that many tumors lack the ability to recruit cytotoxic T cells, which can render them resistant to current immunotherapies. Strategies that reinforce the migration of T cells into tumors are therefore urgently needed to complement existing treatments. Our laboratory focuses on the development of pharmacological approaches to enhance antitumor immune responses, in particular by enhancing T-cell recruitment to tumors and by developing new strategies for drug delivery.
One approach for inducing antitumor immunity is to mimic the immune activation resulting from infectious agents by using synthetic ligands. Two receptor families of the innate immune system play a key role in the detection of microbial agents: the membrane-bound Toll-like receptors (TLRs) and the cytoplasmic RIG-I-like receptors (RLRs). The controlled pharmacological activation of these receptors to induce anticancer immune responses represents the major focus of our laboratory.


University of Fribourg - Chair of Pharmacology

Chemin du Musée 5
1700 Fribourg
Klinische Forschung